BofA Securities Maintains Organon & Co(OGN.US) With Sell Rating, Announces Target Price $15
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $26
BofA Securities Maintains Organon & Co(OGN.US) With Sell Rating
Evercore Maintains Organon & Co(OGN.US) With Buy Rating
Piper Sandler Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $24
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $26
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $26
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $18
TD Cowen Initiates Organon & Co(OGN.US) With Hold Rating, Announces Target Price $27
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $26
Barclays Keeps Their Buy Rating on Organon (OGN)
Evercore Initiates Organon & Co(OGN.US) With Buy Rating
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Organon Analyst Ratings
J.P. Morgan Downgrades Organon & Co(OGN.US) to Sell Rating, Raises Target Price to $20
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $26
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $26
Organon Analyst Ratings
Organon Analyst Ratings
Goldman Sachs Maintains Neutral on Organon, Raises Price Target to $20